

**TOXICOLOGICAL PROFILE FOR
URANIUM**

**U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service
Agency for Toxic Substances and Disease Registry**

September 1999

DISCLAIMER

The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry.

UPDATE STATEMENT

A Toxicology Profile for Uranium was released in September 1997. This edition supersedes any previously released draft or final profile.

Toxicological profiles are revised and republished as necessary, but no less than once every three years. For information regarding the update status of previously released profiles, contact ATSDR at:

Agency for Toxic Substances and Disease Registry
Division of Toxicology/Toxicology Information Branch
1600 Clifton Road NE, E-29
Atlanta, Georgia 30333

FOREWORD

The Superfund Amendments and Reauthorization Act (SARA) of 1986 (Public Law 99-499) extended and amended the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund). This public law directed the Agency for Toxic Substances and Disease Registry (ATSDR) to prepare toxicological profiles for hazardous substances which are most commonly found at facilities on the CERCLA National Priorities List and which pose the most significant potential threat to human health, as determined by ATSDR and the Environmental Protection Agency (EPA). The lists of the 250 most significant hazardous substances were published in the *Federal Register* on April 17, 1987, October 20, 1988, October 26, 1989, and on October 17, 1990.

Section 104 (I) (3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list. Each profile must include the following content:

- (A) An examination, summary, and interpretation of available toxicological information and epidemiological evaluations on the hazardous substance in order to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects,
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure which present a significant risk to human health of acute, subacute, and chronic health effects, and
- (C) Where appropriate, an identification of toxicological testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

This toxicological profile is prepared in accordance with guidelines developed by ATSDR and EPA. The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary, but no less often than every three years, as required by SARA.

The ATSDR toxicological profile is intended to characterize succinctly the toxicological and adverse health effects information for the hazardous substance being described. Each profile identifies and reviews the key literature (that has been peer-reviewed) that describes a hazardous substance's toxicological properties. Other pertinent literature is also presented but described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

Each toxicological profile begins with a public health statement, which describes in nontechnical language a substance's relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, where known, significant health effects. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to protection of public health will be identified by ATSDR, the National Toxicology Program (NTP) of the Public Health Service, and EPA. The focus of the profiles is on health and toxicological information; therefore, we have included this information in the beginning of the document.

This profile reflects our assessment of all relevant toxicological testing and information that has been peer reviewed. It has been reviewed by scientists from ATSDR, the Centers for Disease Control and Prevention, the NTP, and other federal agencies. It has also been reviewed by a panel of nongovernment peer reviewers and is being made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.

Jeffrey P. Koplan, M.D., M.P.H.
Administrator
Agency for Toxic Substances and
Disease Registry

QUICK REFERENCE FOR HEALTH CARE PROVIDERS

Toxicological Profiles are a unique compilation of toxicological information on a given hazardous substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation of available toxicologic and epidemiologic information on a substance. Health care providers treating patients potentially exposed to hazardous substances will find the following information helpful for fast answers to often-asked questions.

Primary Chapters/Sections of Interest

Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating patients about possible exposure to a hazardous substance. It explains a substance's relevant toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of the general health effects observed following exposure.

Chapter 2: Health Effects: Specific health effects of a given hazardous compound are reported by *route of exposure*, by *type of health effect* (death, systemic, immunologic, reproductive), and by *length of exposure* (acute, intermediate, and chronic). In addition, both human and animal studies are reported in this section.

NOTE: Not all health effects reported in this section are necessarily observed in the clinical setting. Please refer to the Public Health Statement to identify general health effects observed following exposure.

Pediatrics: Four new sections have been added to each Toxicological Profile to address child health issues:

Section 1.6	How Can (Chemical X) Affect Children?
Section 1.7	How Can Families Reduce the Risk of Exposure to (Chemical X)?
Section 2.6	Children's Susceptibility
Section 5.6	Exposures of Children

Other Sections of Interest:

Section 2.7	Biomarkers of Exposure and Effect
Section 2.10	Methods for Reducing Toxic Effects

ATSDR Information Center

Phone: 1-888-42-ATSDR or 404-639-6357 **Fax:** 404-639-6359
E-mail: atsdric@cdc.gov **Internet:** <http://atsdr1.atsdr.cdc.gov:8080>

The following additional material can be ordered through the ATSDR Information Center:

Case Studies in Environmental Medicine: Taking an Exposure History—The importance of taking an exposure history and how to conduct one are described, and an example of a thorough exposure history is provided. Other case studies of interest include *Reproductive and Developmental Hazards*; *Skin Lesions and Environmental Exposures*; *Cholinesterase-Inhibiting Pesticide Toxicity*; and numerous chemical-specific case studies.

Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene (prehospital) and hospital medical management of patients exposed during a hazardous materials incident. Volumes I and II are planning guides to assist first responders and hospital emergency department personnel in planning for incidents that involve hazardous materials. Volume III—*Medical Management Guidelines for Acute Chemical Exposures*—is a guide for health care professionals treating patients exposed to hazardous materials.

Fact Sheets (ToxFAQs) provide answers to frequently asked questions about toxic substances.

Other Agencies and Organizations

The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, injury, and disability related to the interactions between people and their environment outside the workplace. *Contact:* NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015.

The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational diseases and injuries, responds to requests for assistance by investigating problems of health and safety in the workplace, recommends standards to the Occupational Safety and Health Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains professionals in occupational safety and health. *Contact:* NIOSH, 200 Independence Avenue, SW, Washington, DC 20201 • Phone: 800-356-4674 or NIOSH Technical Information Branch, Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998 • Phone: 800-35-NIOSH.

The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for biomedical research on the effects of chemical, physical, and biologic environmental agents on human health and well-being. *Contact:* NIEHS, PO Box 12233, 104 T.W. Alexander Drive, Research Triangle Park, NC 27709 • Phone: 919-541-3212.

Referrals

The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics in the United States to provide expertise in occupational and environmental issues. *Contact:* AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone: 202-347-4976 • FAX: 202-347-4950 • e-mail: aoec@dgs.dgsys.com • AOEC Clinic Director: <http://occ-env-med.mc.duke.edu/oem/aoec.htm>.

The American College of Occupational and Environmental Medicine (ACOEM) is an association of physicians and other health care providers specializing in the field of occupational and environmental medicine. *Contact:* ACOEM, 55 West Seegers Road, Arlington Heights, IL 60005 • Phone: 847-228-6850 • FAX: 847-228-1856.

CONTRIBUTORS

CHEMICAL MANAGER(S)/AUTHORS(S):

Sam Keith, M.S., CHP
ATSDR, Division of Toxicology, Atlanta, GA

Wayne Spoo, DVM, DABT
Research Triangle Institute, Research Triangle Park, NC

James Corcoran, Ph.D.
Research Triangle Institute, Research Triangle Park, NC

THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:

1. Health Effects Review. The Healths Effects Review Committee examines the health effects chapter of each profile for consistency and accuracy in interpreting health effects and classifying end points.
2. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to substance-specific minimal risk levels (MRLs), reviews the health effects database of each profile, and makes recommendations for derivation of MRLs.

PEER REVIEW

A peer review panel was assembled for uranium. The panel consisted of the following members:

1. Herman Cember, Ph.D., CHP, Lafayette, Indiana
2. Ron Kathren, Ph.D., CHP, Professor, Richland, Washington.
3. Paul Morrow, Ph.D., Professor Emeritus, Rochester, New York.
4. Richard Leggett, Ph.D., Research Scientist, Oak Ridge, Tennessee.
5. Darrell Fisher, Ph.D., Senior Scientist, Richland, Washington

These experts collectively have knowledge of the physical and chemical properties, toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and quantification of risk to humans of uranium and uranium compounds. All reviewers were selected in conformity with the conditions for peer review specified in Section 104(i)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer reviewers' comments and determined which comments will be included in the profile. A listing of the peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their exclusion, exists as part of the administrative record for this compound. A list of databases reviewed and a list of unpublished documents cited are also included in the administrative record.

The citation of the peer review panel should not be understood to imply its approval of the profile's final content. The responsibility for the content of this profile lies with the ATSDR.

CONTENTS

FOREWORD	v
QUICK REFERENCE FOR HEALTH CARE PROVIDERS	vii
CONTRIBUTORS	ix
PEER REVIEW	xi
LIST OF FIGURES	xvii
LIST OF TABLES	xix
1. PUBLIC HEALTH STATEMENT	1
1.1 WHAT IS URANIUM?	1
1.2 WHAT HAPPENS TO URANIUM WHEN IT ENTERS THE ENVIRONMENT?	5
1.3 HOW MIGHT I BE EXPOSED TO URANIUM?	7
1.4 HOW CAN URANIUM ENTER AND LEAVE MY BODY?	8
1.5 HOW CAN URANIUM AFFECT MY HEALTH?	9
1.6 HOW CAN URANIUM AFFECT CHILDREN?	10
1.7 HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO URANIUM?	11
1.8 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO URANIUM?	12
1.9 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT HUMAN HEALTH?	13
1.10 WHERE CAN I GET MORE INFORMATION?	14
2. HEALTH EFFECTS	17
2.1 INTRODUCTION	17
2.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE	24
2.2.1 Inhalation Exposure	26
2.2.1.1 Death	27
2.2.1.2 Systemic Effects	30
2.2.1.3 Immunological and Lymphoreticular Effects	81
2.2.1.4 Neurological Effects	83
2.2.1.5 Reproductive Effects	84
2.2.1.6 Developmental Effects	85
2.2.1.7 Genotoxic Effects	85
2.2.1.8 Cancer	86
2.2.2 Oral Exposure	92
2.2.2.1 Death	92
2.2.2.2 Systemic Effects	93
2.2.2.3 Immunological and Lymphoreticular Effects	132
2.2.2.4 Neurological Effects	133
2.2.2.5 Reproductive Effects	133
2.2.2.6 Developmental Effects	135
2.2.2.7 Genotoxic Effects	136
2.2.2.8 Cancer	137
2.2.3 Dermal Exposure	138

2.2.3.1	Death	138
2.2.3.2	Systemic Effects	139
2.2.3.3	Immunological and Lymphoreticular Effects	148
2.2.3.4	Neurological Effects	149
2.2.3.5	Reproductive Effects	149
2.2.3.6	Developmental Effects	149
2.2.3.7	Genotoxic Effects	149
2.2.3.8	Cancer	149
2.3	TOXICOKINETICS	150
2.3.1	Absorption	150
2.3.1.1	Inhalation Exposure	150
2.3.1.2	Oral Exposure	152
2.3.1.3	Dermal Exposure	153
2.3.2	Distribution	154
2.3.2.1	Inhalation Exposure	154
2.3.2.2	Oral Exposure	157
2.3.2.3	Dermal Exposure	159
2.3.2.4	Other Routes of Exposure	159
2.3.3	Metabolism	160
2.3.4	Elimination and Excretion	160
2.3.4.1	Inhalation Exposure	160
2.3.4.2	Oral Exposure	163
2.3.4.3	Dermal Exposure	164
2.3.5	Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models	164
2.4	MECHANISMS OF ACTION	181
2.4.1	Pharmacokinetic Mechanisms	181
2.4.2	Mechanisms of Toxicity	182
2.4.3	Animal-to-Human Extrapolations	185
2.5	RELEVANCE TO PUBLIC HEALTH	186
2.6	CHILDREN'S SUSCEPTIBILITY	212
2.7	BIOMARKERS OF EXPOSURE AND EFFECT	215
2.7.1	Biomarkers Used to Identify or Quantify Exposure to Uranium	216
2.7.2	Biomarkers Used to Characterize Effects Caused by Uranium	217
2.8	INTERACTIONS WITH OTHER CHEMICALS	218
2.9	POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE	218
2.10	METHODS FOR REDUCING TOXIC EFFECTS	219
2.10.1	Reducing Peak Absorption Following Exposure	219
2.10.2	Reducing Body Burden	219
2.10.3	Interfering with the Mechanism of Action for Toxic Effects	220
2.11	ADEQUACY OF THE DATABASE	220
2.11.1	Existing Information on Health Effects of Uranium	220
2.11.2	Identification of Data Needs	223
2.11.3	Ongoing Studies	232
3.	CHEMICAL AND PHYSICAL INFORMATION	235
3.1	CHEMICAL IDENTITY	235
3.2	PHYSICAL, CHEMICAL, AND RADIOLOGICAL PROPERTIES	235

4. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL	245
4.1 PRODUCTION	245
4.2 IMPORT/EXPORT	249
4.3 USE	253
4.4 DISPOSAL	253
5. POTENTIAL FOR HUMAN EXPOSURE	257
5.1 OVERVIEW	257
5.2 RELEASES TO THE ENVIRONMENT	262
5.2.1 Air	262
5.2.2 Water	266
5.2.3 Soil	267
5.3 ENVIRONMENTAL FATE	270
5.3.1 Transport and Partitioning	270
5.3.2 Transformation and Degradation	276
5.3.2.1 Air	276
5.3.2.2 Water	276
5.3.2.3 Sediment and Soil	277
5.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT	278
5.4.1 Air	278
5.4.2 Water	280
5.4.3 Soil	285
5.4.4 Other Environmental Media	287
5.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE	289
5.6 EXPOSURES OF CHILDREN	291
5.7 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES	293
5.8 ADEQUACY OF THE DATABASE	294
5.8.1 Identification of Data Needs	294
5.8.2 Ongoing Studies	297
6. ANALYTICAL METHODS	299
6.1 BIOLOGICAL MATERIALS	299
6.1.1 Internal Uranium Measurements	299
6.1.2 <i>In Vivo</i> and <i>In Vitro</i> Uranium Measurements	300
6.2 ENVIRONMENTAL SAMPLES	304
6.2.1 Field Measurements of Uranium	304
6.2.2 Laboratory Analysis of Environmental Samples	305
6.3 ADEQUACY OF THE DATABASE	315
6.3.1 Identification of Data Needs	315
6.3.2 Ongoing Studies	316
7. REGULATIONS AND ADVISORIES	319
8. REFERENCES	333
9. GLOSSARY	381

LIST OF APPENDICES

A.	ATSDR MINIMAL RISK LEVELS AND WORKSHEETS	A-1
B.	USER'S GUIDE	B-1
C.	ACRONYMS, ABBREVIATIONS, AND SYMBOLS	C-1
D.	OVERVIEW OF BASIC RADIATION PHYSICS, CHEMISTRY AND BIOLOGY	D-1
I.	INDEX	I-1

LIST OF FIGURES

2-1	Levels of Significant Exposure to Uranium, Inhalation—Chemical Toxicity	54
2-2	Levels of Significant Exposure to Uranium, Inhalation—Radiation Toxicity	64
2-3	Levels of Significant Exposure to Uranium, Oral—Chemical Toxicity	115
2-4	Conceptual Representation of a Physiologically Based Pharmacokinetic (PBPK) Model for a Hypothetical Chemical Substance	166
2-5	Respiratory Tract Compartments in Which Particles May Be Deposited	168
2-6	Compartment Model to Represent Time-Dependent Particle Transport in the Respiratory Tract	170
2-7	The Human Respiratory Tract Model: Absorption into Blood	175
2-8	Biokinetic Model for Uranium After Uptake to Blood	177
2-9	Multicompartmental Model	178
2-10	Existing Information on the Health Effects of Uranium	222
4-1	Flow Chart of Uranium Ore Processing	248
5-1	Frequency of NPL Sites with Uranium (U-238) Contamination	258
5-2	Major DOE Offices, Facilities, and Laboratories	264
5-3	Environmental Pathways for Potential Human Health Effects from Uranium	271
5-4	Average Uranium Concentrations in Drinking Water for States Where Concentration Exceeds 1 pCi/L	281
7-1	Nuclear Regulatory Commission Agreement States	332

LIST OF TABLES

2-1	Levels of Significant Exposure to Uranium, Chemical Toxicity—Inhalation	31
2-2	Levels of Significant Exposure to Uranium, Radiation Toxicity—Inhalation	63
2-3	Levels of Significant Exposure to Uranium, Chemical Toxicity—Oral	94
2-4	Levels of Significant Exposure to Uranium, Chemical Toxicity—Dermal	140
2-5	Reference Respiratory Values for a General Caucasian Population at Different Levels of Activity	169
2-6	Reference Values of Parameters for the Compartment Model to Represent Time-dependent Particle Transport from the Human Respiratory Tract	172
2-7	Sensitivity and Calculated Transfer Coefficients (d^{-1})	180
2-8	Enriched, Natural, and Depleted Uranium Mass Equivalents for Radiological Effects	193
2-9	Genotoxicity of Uranium <i>In Vivo</i>	209
2-10	Genotoxicity of Uranium <i>In Vitro</i>	210
2-11	Ongoing Studies on Health Effects of Uranium	233
3-1	Chemical Identity of Uranium Metal	236
3-2	Physical and Chemical Properties of Selected Uranium Compounds	237
3-3	Percent Occurrence and Radioactive Properties of Naturally Occurring Isotopes of Uranium	240
3-4	Uranium Isotope Decay Series Showing the Decay Products of the Naturally Occurring Isotopes of Uranium	241
4-1	Uranium Ores	246
4-2	Uranium Production in the United States by Uranium Mills and Other Sources	250
4-3	Uranium Mining Production, 1985–1998	251
4-4	Import of Uranium and Compounds (in kg) into the United States	252
4-5	Export of Uranium and Compounds (in kg)	254

5-1	Normalized Uranium Effluent Discharges from Uranium Mining, Milling, Conversion, Enrichment, and Fuel Fabrication	268
5-2	Uranium in Airborne Particles (Composites)	279
5-3	Uranium Analyses of Select Precipitation Composite Samples March–May 1993	283
5-4	Uranium in Rocks and Soils	286
5-5	Concentrations of Uranium in Some Foods	288
5-6	Ongoing Studies on Environmental Effects of Uranium	298
6-1	Analytical Methods for Determining Uranium in Biological Samples	302
6-2	Analytical Methods for Determining Uranium in Environmental Samples	306
6-3	Additional Analytical Methods for Determining Uranium in Environmental Samples	313
6-4	Ongoing Studies on Analytical Methods for Uranium	317
7-1	Regulations and Guidelines Applicable to Uranium	324